Quantitative control of sialylation and specific mono-sialylation

US9481902B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Tibor Czabany · Graz, AT
• Alfred Engel · Tutzing, DE
• Michael Greif · Penzberg, DE
• Christine Jung · Iffeldorf, DE
• Christiane Luley · Eferding, AT
• Sebastian Malik · Antdorf, DE
• Rainer Mueller · Penzberg, DE
• Bernd Nidetzky · Graz, AT
• Doris Ribitsch · Graz, AT
• Katharina Schmoelzer · Graz, AT
• Helmut Schwab · Graz, AT
• Harald Sobek · Penzberg, DE
• Bernhard Suppmann · Weilheim, DE
• Marco Thomann · Beuerberg, DE
• Sabine Zitzenbacher · Graz, AT

Key dates

• Filing date: Dec 16, 2015
• Grant date: Nov 1, 2016
• Expiry date: Dec 16, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/41
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. It was found that the combination of two different truncation variants of human β-galactoside-α-2,6-sialyltransferase I (hST6Gal-I) exhibited different specific sialyltransferase enzymatic activities. In one example, under conditions wherein the first variant Δ89 hST6Gal-I catalyzed formation of bi-sialylated target molecules the second variant Δ108 hST6Gal-I catalyzed formation of mono-sialylated target molecules. Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.